Vamil Divan
Stock Analyst at Guggenheim
(4.67)
# 200
Out of 4,412 analysts
149
Total ratings
66.15%
Success rate
16.09%
Average return
Main Sectors:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $77 | $65.36 | +17.81% | 8 | Apr 23, 2024 | |
| ALPN Alpine Immune Sciences | Initiates: Buy | $55 | $64.56 | -14.81% | 1 | Apr 9, 2024 | |
| VERA Vera Therapeutics | Reiterates: Buy | $56 | $39.65 | +41.24% | 3 | Apr 5, 2024 | |
| TVTX Travere Therapeutics | Downgrades: Neutral | n/a | $5.26 | - | 4 | Mar 27, 2024 | |
| ABBV AbbVie | Maintains: Buy | $188 → $190 | $159.62 | +19.03% | 16 | Mar 22, 2024 | |
| INSM Insmed | Maintains: Buy | $52 → $54 | $24.80 | +117.74% | 3 | Feb 27, 2024 | |
| PFE Pfizer | Initiates: Buy | $36 | $25.40 | +41.73% | 12 | Feb 23, 2024 | |
| RVNC Revance Therapeutics | Downgrades: Neutral | $16 → $9 | $3.40 | +164.71% | 4 | Jan 29, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $19 → $20 | $13.69 | +46.09% | 7 | Sep 7, 2023 | |
| CALT Calliditas Therapeutics AB (publ) | Maintains: Neutral | $21 → $18 | $19.50 | -7.70% | 2 | Aug 18, 2023 | |
| RLMD Relmada Therapeutics | Reiterates: Buy | $26 | $3.83 | +578.85% | 2 | Jun 15, 2023 | |
| SCYX SCYNEXIS | Maintains: Buy | $8 → $9 | $1.54 | +484.42% | 2 | Apr 3, 2023 | |
| AVTE Aerovate Therapeutics | Initiates: Buy | $36 | $21.75 | +65.52% | 1 | Mar 1, 2023 | |
| GOSS Gossamer Bio | Initiates: Neutral | n/a | $0.67 | - | 1 | Mar 1, 2023 | |
| JNJ Johnson & Johnson | Initiates: Neutral | $161 | $146.14 | +10.17% | 6 | Mar 1, 2023 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $27 → $19 | $16.71 | +13.70% | 7 | Aug 10, 2022 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $95 → $98 | $135.99 | -27.94% | 5 | Aug 8, 2022 | |
| ALKS Alkermes | Maintains: Buy | $36 → $34 | $24.68 | +37.76% | 7 | Jul 28, 2022 | |
| CABA Cabaletta Bio | Maintains: Buy | $20 → $10 | $11.01 | -9.17% | 3 | May 25, 2022 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $51 → $49 | $71.71 | -31.67% | 3 | May 3, 2022 | |
| LLY Eli Lilly | Maintains: Buy | $315 → $356 | $733.51 | -51.47% | 12 | May 2, 2022 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $8 → $6 | $1.75 | +242.86% | 1 | Mar 16, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | $144 → $154 | $38.97 | +295.18% | 9 | Mar 3, 2022 | |
| EOLS Evolus | Upgrades: Buy | n/a | $11.43 | - | 4 | May 6, 2021 | |
| TEVA Teva Pharmaceutical | Maintains: Neutral | n/a | $13.81 | - | 10 | Feb 14, 2019 | |
| GLPG Galapagos NV | Upgrades: Outperform | n/a | $28.76 | - | 3 | Dec 13, 2018 | |
| MRK Merck & Co. | Maintains: Outperform | n/a | $131.20 | - | 5 | Oct 11, 2018 | |
| CRVS Corvus Pharmaceuticals | Assumes: Outperform | n/a | $1.45 | - | 3 | Aug 15, 2018 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | n/a | $44.85 | - | 3 | Jul 27, 2018 | |
| ESPR Esperion Therapeutics | Initiates: Outperform | n/a | $1.90 | - | 2 | Jan 17, 2018 |
ANI Pharmaceuticals
Apr 23, 2024
Reiterates: Buy
Price Target: $77
Current: $65.36
Upside: +17.81%
Alpine Immune Sciences
Apr 9, 2024
Initiates: Buy
Price Target: $55
Current: $64.56
Upside: -14.81%
Vera Therapeutics
Apr 5, 2024
Reiterates: Buy
Price Target: $56
Current: $39.65
Upside: +41.24%
Travere Therapeutics
Mar 27, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.26
Upside: -
AbbVie
Mar 22, 2024
Maintains: Buy
Price Target: $188 → $190
Current: $159.62
Upside: +19.03%
Insmed
Feb 27, 2024
Maintains: Buy
Price Target: $52 → $54
Current: $24.80
Upside: +117.74%
Pfizer
Feb 23, 2024
Initiates: Buy
Price Target: $36
Current: $25.40
Upside: +41.73%
Revance Therapeutics
Jan 29, 2024
Downgrades: Neutral
Price Target: $16 → $9
Current: $3.40
Upside: +164.71%
Sage Therapeutics
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $13.69
Upside: +46.09%
Calliditas Therapeutics AB (publ)
Aug 18, 2023
Maintains: Neutral
Price Target: $21 → $18
Current: $19.50
Upside: -7.70%
Relmada Therapeutics
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $3.83
Upside: +578.85%
SCYNEXIS
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $1.54
Upside: +484.42%
Aerovate Therapeutics
Mar 1, 2023
Initiates: Buy
Price Target: $36
Current: $21.75
Upside: +65.52%
Gossamer Bio
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.67
Upside: -
Johnson & Johnson
Mar 1, 2023
Initiates: Neutral
Price Target: $161
Current: $146.14
Upside: +10.17%
ACADIA Pharmaceuticals
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $16.71
Upside: +13.70%
Neurocrine Biosciences
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $135.99
Upside: -27.94%
Alkermes
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $24.68
Upside: +37.76%
Cabaletta Bio
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $11.01
Upside: -9.17%
Axsome Therapeutics
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $71.71
Upside: -31.67%
Eli Lilly
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $733.51
Upside: -51.47%
Xeris Biopharma Holdings
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $1.75
Upside: +242.86%
Biohaven Pharmaceutical Holding Company
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $38.97
Upside: +295.18%
Evolus
May 6, 2021
Upgrades: Buy
Price Target: n/a
Current: $11.43
Upside: -
Teva Pharmaceutical
Feb 14, 2019
Maintains: Neutral
Price Target: n/a
Current: $13.81
Upside: -
Galapagos NV
Dec 13, 2018
Upgrades: Outperform
Price Target: n/a
Current: $28.76
Upside: -
Merck & Co.
Oct 11, 2018
Maintains: Outperform
Price Target: n/a
Current: $131.20
Upside: -
Corvus Pharmaceuticals
Aug 15, 2018
Assumes: Outperform
Price Target: n/a
Current: $1.45
Upside: -
Bristol-Myers Squibb Company
Jul 27, 2018
Maintains: Neutral
Price Target: n/a
Current: $44.85
Upside: -
Esperion Therapeutics
Jan 17, 2018
Initiates: Outperform
Price Target: n/a
Current: $1.90
Upside: -